This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective of this study is to document pharmacodynamic activity as determined by immunofluorescence evidence of dystrophin expression in the muscle (negative at baseline versus positive results after treatment) with a dosing regimen that can be safely administered. The protocol will assess other measures of pharmacological activity, evaluate drug compliance, and evaluate PTC124 safety and PK in DMD subjects. Based on the characterization of PTC124 from this study, clinical development of the drug for use in subjects with DMD will continue in a registration-directed clinical trials program.
Showing the most recent 10 out of 535 publications